Sugi Predict

Sugi Predict / Compounds / SCHEMBL481973

SCHEMBL481973

SCHEMBL481973

O=C(O)N[C@H]1CC[C@H](O)CC1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 3/20 0.68
▸ POLB P06746 1/20 0.43
▸ MMP2 P08253 1/20 0.41
▸ MMP8 P22894 1/20 0.41
▸ EPHX1 P07099 7/20 0.39
▸ NPC1 O15118 4/20 0.39
▸ RAB9A P51151 4/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ MFN2 O95140 1/20 0.37
▸ PKM P14618 2/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1498319 1.00 EPHX2 (0.68) EPHX2POLBMMP2MMP8EPHX1
SCHEMBL481972 1.00 EPHX2 (0.68) EPHX2POLBMMP2MMP8EPHX1
SCHEMBL14635075 0.91 EPHX2 (0.58) EPHX2POLBMMP2MMP8EPHX1
SCHEMBL14635074 0.91 EPHX2 (0.58) EPHX2POLBMMP2MMP8EPHX1
SCHEMBL14635076 0.91 EPHX2 (0.58) EPHX2POLBMMP2MMP8EPHX1
SCHEMBL6658887 0.89 EPHX2 (0.50) EPHX2POLBMMP2MMP8EPHX1
SCHEMBL245467 0.89 — —
Hydrochloric Acid SCHEMBL11416981 0.86 — —
Pentane SCHEMBL15881674 0.85 EPHX2 (0.52) EPHX2EPHX1MAPTALDH1A1MEN1
SCHEMBL23548407 0.85 EPHX2 (0.50) EPHX2POLBMMP2MMP8EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917509-A1 TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF Mitochondria Emotion, Inc. (US) 2021-12-08 — — EP claimed
WO-2020159797-A1 TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF MITOCHONDRIA EMOTION, INC. (US) 2020-08-06 — — WO claimed
US-20240294506-A1 CDK2 INHIBITORS PFIZER INC. (US) 2024-09-05 — — US disclosed
US-12043612-B2 Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same ARVINAS OPERATIONS, INC. (US) 2024-07-23 — — US disclosed
US-20240239790-A1 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor LIFEARC (GB) 2024-07-18 — — US disclosed
US-20240228508-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2024-07-11 — — US disclosed
EP-4384520-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2024-06-19 — — EP disclosed
US-20240182479-A1 SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS ASTRAZENECA AB (SE) 2024-06-06 — — US disclosed
WO-2024112854-A1 INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF ODYSSEY THERAPEUTICS, INC. (US) 2024-05-30 — — WO disclosed
US-20240174704-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2024-05-30 — — US disclosed
WO-2024097775-A1 ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS NUVATION BIO INC. (US) 2024-05-10 — — WO disclosed
US-20090099169-A1 Benzofuran Compounds As EP1 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2009-04-16 — — US disclosed
US-20090023724-A1 Heteroaryl compounds, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2009-01-22 — — US disclosed
EP-1935881-A1 ARYL-SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-06-25 — — EP disclosed
EP-1928879-A2 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS Brystol-Myers Squibb Company (US) 2008-06-11 — — EP disclosed
EP-1773791-A1 PYRROLOTRIAZINE COMPOUNDS Bristol-Myers Squibb Company (US) 2007-04-18 — — EP disclosed
WO-2007038314-A2 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-05 — — WO disclosed
EP-1768658-A1 HYDROXYALKYLAMIDES F.HOFFMANN-LA ROCHE AG (CH) 2007-04-04 — — EP disclosed
WO-2006125451-A1 HYDROXYALKYLAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2006-11-30 — — WO disclosed
WO-2006007468-A1 PYRROLOTRIAZINE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-01-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239790-A1 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor DCK, ERCC2, POLK EPHX2 3100/4885POLB 39/4885MMP2 1772/4885
US-20240228508-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS JAK1, JAK3, JAK2 EPHX2 3667/4885POLB 2451/4885MMP2 4345/4885
US-20090099169-A1 Benzofuran Compounds As EP1 Receptor Antagonists PTGER1, PTGER2, PTGER3 EPHX2 990/4885POLB 1936/4885MMP2 4197/4885
US-12043612-B2 Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same PAICS, UGT1A1, PBRM1 EPHX2 1754/4885POLB 1359/4885MMP2 4075/4885
US-20240174704-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 EPHX2 4254/4885POLB 4269/4885MMP2 1794/4885
US-20240294506-A1 CDK2 INHIBITORS CDK2, CDK1, CCNI EPHX2 2617/4885POLB 634/4885MMP2 3283/4885
US-20240182479-A1 SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS IRAK4, IRAK3, IRAK2 EPHX2 4351/4885POLB 3873/4885MMP2 4104/4885
US-20090023724-A1 Heteroaryl compounds, compositions thereof, and methods of treatment therewith JAK2, PHKG1, PHKG2 EPHX2 1092/4885POLB 1632/4885MMP2 2203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.